Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257927 | 1.00 | PRMT1 (0.63) | PRMT1ADRA1AMAPK1EPHX2LMNA | |
| SCHEMBL30905813 | 0.96 | PRMT1 (0.59) | PRMT1ADRA1AMAPK1EPHX2LMNA | |
| SCHEMBL1927840 | 0.87 | ALDH1A1 (0.59) | PRMT1MAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1927654 | 0.87 | ALDH1A1 (0.59) | PRMT1MAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24483715 | 0.85 | PRMT1 (0.71) | PRMT1ADRA1AMAPK1EPHX2LMNA | |
| SCHEMBL11468363 | 0.85 | PRMT1 (0.71) | PRMT1ADRA1AMAPK1EPHX2LMNA | |
| SCHEMBL8507619 | 0.85 | PRMT1 (0.71) | PRMT1ADRA1AMAPK1EPHX2LMNA | |
| SCHEMBL17767810 | 0.85 | PRMT1 (0.71) | PRMT1ADRA1AMAPK1EPHX2LMNA | |
| SCHEMBL22506195 | 0.85 | PRMT1 (0.71) | PRMT1ADRA1AMAPK1EPHX2LMNA | |
| SCHEMBL8766995 | 0.85 | PRMT1 (0.71) | PRMT1ADRA1AMAPK1EPHX2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148577-B1 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE | BIOLOGICAL E LTD (IN) | 2021-01-20 | — | — | EP | claimed |
| US-20170198004-A1 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE | BIOLOGICAL E LTD (IN) | 2017-07-13 | — | — | US | claimed |
| EP-3148577-A2 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE | Biological E Limited (IN) | 2017-04-05 | — | — | EP | claimed |
| WO-2015181834-A2 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE | BIOLOGICAL E LIMITED (IN) | 2015-12-03 | — | — | WO | claimed |
| EP-2478049-B1 | A POLYMER SUPPORT | UNIV CAPE TOWN (ZA) | 2015-02-25 | — | — | EP | claimed |
| EP-2171457-B1 | IMPROVEMENTS IN OR RELATING TO PRODUCTION OF CONJUGATES | INNOVA BIOSCIENCES LTD (GB) | 2013-07-10 | — | — | EP | claimed |
| EP-2488208-A1 | COMPOUNDS HAVING PEPTIDES CONJUGATED TO BONE TARGETING MOIETIES AND METHODS OF MAKING AND USING THEREOF | The Governors of the University of Alberta (CA) | 2012-08-22 | — | — | EP | claimed |
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-09-22 | — | — | US | claimed |
| EP-2315771-A2 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | Sloan Kettering Institute For Cancer Research (US) | 2011-05-04 | — | — | EP | claimed |
| WO-2010006343-A2 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-01-14 | — | — | WO | claimed |
| EP-0996455-B1 | ALPHA-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 2009-12-16 | — | — | EP | claimed |
| CN-118852478-A | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | 格莱克罗吉克斯公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118541159-A | Methods of producing TIL products using PD-1 TALEN gene knockdown | 艾欧凡斯生物治疗公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-115697352-B | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | 格莱克罗吉克斯公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | GLYCOLOGIX INC (US) | 2024-07-18 | — | — | US | disclosed |
| EP-1091751-A1 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-0996455-A1 | $g(a)-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999048515-A9 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999048515-A1 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1998046246-A1 | α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | MATR3, CSGALNACT1, CD44 | PRMT1 4313/4885ADRA1A 4832/4885MAPK1 4457/4885 |
| US-20170198004-A1 | NOVEL SEMI-SYNTHETIC MENINGOCOCCAL CONJUGATE VACCINE | STT3B, CD14, STT3A | PRMT1 1013/4885ADRA1A 4865/4885MAPK1 4244/4885 |
| US-20110229510-A1 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF | B3GAT3, MICA, SIGLEC7 | PRMT1 3624/4885ADRA1A 4846/4885MAPK1 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.